Retinalamin 5mg

1. 1

   Decontaminate the rubber stoppers of the Retinalamin vial and diluent vial using fresh sterile alcohol pads, allowing them to fully air-dry.

2. 2

   Draw precisely 1.0 mL of bacteriostatic water or sterile saline using an appropriate sterile syringe.

3. 3

   Insert the needle at a slight angle and discharge the fluid gently against the internal glass wall to prevent foaming of delicate peptide fractions.

4. 4

   Carefully roll or swirl the vial between your palms until the lyophilizate fully clears; avoid vigorous shaking.

5. 5

   Visually inspect the dissolved solution to verify clarity and absence of particulate matter before immediate laboratory application.

Overview

Retinalamin is a biological cytomedine complex consisting of low-molecular-weight peptide fractions harvested from bovine retinal tissue. Originally developed and registered for clinical use in Russia and select CIS nations, it is classified as a tissue-specific peptide bioregulator intended to support retinal cellular health and neuroprotection. Unlike synthetic single-chain signaling peptides, Retinalamin is an organic biological extract containing a spectrum of peptide fragments that mirror the native composition of ocular structures. In experimental and clinical environments, the complex is primarily evaluated for its therapeutic potential in ocular conditions such as diabetic retinopathy, open-angle glaucoma, and general retinal degeneration. Researchers focus on how these extracted fractions may mitigate excitotoxic stress and preserve retinal ganglion cells and photoreceptor function. Despite its regulatory approval in regional Eastern European markets, the agent lacks approval from the FDA or EMA and has not been corroborated by Western double-blind randomized clinical trials. From a laboratory perspective, Retinalamin presents unique handling requirements due to its animal-derived natural origin. Batch uniformity is governed by strict extraction protocols rather than synthetic chemical synthesis. Investigational protocols evaluate its systemic biodistribution to ocular and cerebral tissues, typically utilizing whole-vial dosing regimens to study systemic retinal cellular responses.

1. 1.Verlov et al., Vestnik Oftalmologii, 2021 — Ligand-receptor interaction and biodistribution of a drug containing cattle retinal polypeptides
2. 2.Gabdrakhmanova et al., Vestnik Oftalmologii, 2018 — Molecular mechanisms of neuroretinoprotection in primary open-angle glaucoma
3. 3.Malakhova et al., Vestnik Oftalmologii, 2024 — Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy
4. 4.Dorofeev et al., Vestnik Oftalmologii, 2021 — Effect of retinal protective therapy on optical coherence tomography angiography (pilot study)
5. 5.Kharintseva, Advances in Gerontology, 2011 — Retinoprotective therapy of diabetic macular edema in elderly patients

Peptide VialView

Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.